• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

How the Tokyo Olympics Changed the Conversation About Athletes ’ Mental Health
Even before Simone Biles threw the Olympics off its axis, Jessica Bartley knew mental health issues were weighing heavily on the athletes in Tokyo. Bartley, a psychologist and the director of mental health services for the U.S. Olympic and Paralympic Committee, says her team received about 10 requests daily during the Games to support athletes’ mental health needs. Most of the calls did not come directly from athletes, but from “a tip from someone around the athlete, who alerted us to a situation,” she says. These requests involved everything from struggles while in quarantine due to COVID-19 protocols, t...
Source: TIME: Health - August 8, 2021 Category: Consumer Health News Authors: Alice Park/Tokyo Tags: Uncategorized olympics Tokyo Olympics Source Type: news

Teijin and NeuroSigma Enter into Exclusive License Agreement
Teijin Pharma to Market eTNS for the Treatment of ADHD in Japan LOS ANGELES, Oct. 17, 2019 -- (Healthcare Sales & Marketing Network) -- Teijin Limited (Teijin) and NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company focused on dev... Devices, Neurology, Licensing NeuroSigma, Teijin, Trigeminal Nerve Stimulation, Monarch eTNS
Source: HSMN NewsFeed - October 17, 2019 Category: Pharmaceuticals Source Type: news

Brain ’s support network may play key role in attention deficit, hyperactivity behaviors
A new UCLA study suggests that brain cells called astrocytes, previously thought to provide mainly nourishment and housekeeping functions for neurons, may play a key role in the regulation of attention deficit disorder and hyperactivity.Attention deficit hyperactivity disorder, or ADHD, is estimated to affect about 7 percent  of children and adults in the U.S. Although the disorder has been the subject of much research, as well as scientific and public discussion, in recent years, the causes for the rise in ADHD are still unclear.Theresearch, published in the journal Cell, was led by Baljit Khakh, a professor of physiol...
Source: UCLA Newsroom: Health Sciences - April 25, 2019 Category: Universities & Medical Training Source Type: news

Shire reports positive data from Phase III trial of Intuniv for ADHD
Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder ( …
Source: Drug Development Technology - September 21, 2017 Category: Pharmaceuticals Source Type: news

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan
TOKYO (Reuters) - Shire Plc and Shionogi& Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.
Source: Reuters: Health - September 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

How Digital is Pharma?
Digital transformation will impact pharma in many ways, not least through innovation in medical technology, customer experience for both patients and healthcare professionals, and platforms to facilitate and measure outcomes-based care. What is clear is that companies will need a deep understanding of the digital world and improved internal skills if they are to succeed.To better understand how ready companies were for the digital tidal wave, a year ago, we looked at thedigital intensity of pharma companies, and highlighted J&J ’s strength and the slower response of others, such as AstraZeneca and Pfizer. To measure ...
Source: EyeForPharma - April 26, 2017 Category: Pharmaceuticals Authors: Tina Boggiano Douglas Haggstrom Source Type: news